News Karnataka
Friday, March 29 2024
Cricket
Delhi

Biological E seeks nod for phase 3 trial of Corbevax as booster dose

Cyprus Receives 436000 Vaccines Amid Alarming Spike In Cases
Photo Credit :

New Delhi: Pharma major Biological E has sought approval from drug regulator Drugs Controller General of India to conduct the phase-3 clinical trial of Covid vaccine Corbevax. The company has sought approval as a single booster dose for those fully vaccinated with Covishield or Covaxin vaccines.

The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) may discuss the matter in its next meeting.

The phase 2/3 clinical trials of Corbevax are underway and the results are likely to be declared this month.

Corbevax is based on a protein antigen technology that binds to the Angiotensin Converting Enzyme-2 (ACE2) receptor on the host cell membrane and facilitates virus entry. The body’s own cells stimulate the immune system of the body to produce antibodies to protect against the infection.

Biological E. received DCGI approval for conducting Phase III Comparator Safety & Immunogenicity trial in adults after the Subject Expert Committee’s review of Phase I and II clinical trials data last month. Additionally, Biological E.A also received approval to initiate the Phase II/III Study to evaluate Safety, Reactogenicity, Tolerability and Immunogenicity of CORBEVAX in children and adolescents last month.

The pharma company has submitted the application seeking the nod from DCGA to conduct the phase-3 clinical study of Corbevax.

Share this:
MANY DROPS MAKE AN OCEAN
Support NewsKarnataka's quality independent journalism with a small contribution.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

To get the latest news on WhatsApp